SCHEMBL3015376

SCHEMBL3015376

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3)n2)c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 2/20 0.36
CHRM4 P08173 1/20 0.36
TRPM8 Q7Z2W7 3/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
HTR2A P28223 1/20 0.34
SCN9A Q15858 3/20 0.34
USP2 O75604 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GBA1 P04062 1/20 0.33
AVPR1B P47901 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
KIT P10721 1/20 0.33
C5AR1 P21730 1/20 0.33
SCN4A P35499 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN3A Q9NY46 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008424 0.93 LIPE (0.37) LIPECHRM4TRPM8HTR2AGBA1
SCHEMBL3006198 0.91 LIPE (0.38) LIPECHRM4TRPM8NPC1RAB9A
SCHEMBL3001734 0.88 SMN1; SMN2 (0.40) NPC1RAB9AHTR2AUSP2MAPT
SCHEMBL3021393 0.88 GBA1 (0.42) NPC1RAB9AMAPTGBA1
SCHEMBL3013182 0.87 LMNA (0.37) NPC1RAB9AHTR2AMAPTGBA1
SCHEMBL3014869 0.87 LIPE (0.40) LIPECHRM4TRPM8HTR2AMAPT
SCHEMBL3000012 0.87 CSNK1D (0.37) LIPECHRM4TRPM8USP2MAPT
SCHEMBL3102208 0.86 MAPT (0.47) SCN9AUSP2MAPTRECQLHSD17B10
SCHEMBL3020316 0.86 GBA1 (0.35) NPC1RAB9AMAPTGBA1
SCHEMBL3015608 0.86 SMN1; SMN2 (0.38) NPC1RAB9AMAPTGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LIPE 2030/4885CHRM4 4476/4885TRPM8 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.